{"doi":"10.1038\/sj.bjp.0707478","coreId":"195878","oai":"oai:lra.le.ac.uk:2381\/8005","identifiers":["oai:lra.le.ac.uk:2381\/8005","10.1038\/sj.bjp.0707478"],"title":"Cannabinoid activation of PPAR\u03b1; a novel neuroprotective mechanism","authors":["Sun, Y.","Alexander, S.P.H.","Garle, M.J.","Gibson, Claire L.","Hewitt, K.","Murphy, Sean P.","Kendall, D.A.","Bennett, A.J."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2007-10-01","abstract":"Full text of this item is not currently available on the LRA.  \\ud\nThe final published version is available at http:\/\/www3.interscience.wiley.com\/journal\/121667860\/issue, Doi: 10.1038\/sj.bjp.0707478.Background and purpose: Although CB1 receptor activation evokes neuroprotection in response to cannabinoids, some cannabinoids have been reported to be peroxisome proliferator activated receptor (PPAR) ligands, offering an alternative protective mechanism. We have, therefore, investigated the ability of a range of cannabinoids to activate PPAR\u03b1 and for N-oleoylethanolamine (OEA), an endogenous cannabinoid-like compound (ECL), to evoke neuroprotection.\\ud\nExperimental approach: Assays of PPAR\u03b1 occupancy and gene transactivation potential were conducted in cell-free and transfected HeLa cell preparations, respectively. In vivo estimates of PPAR\u03b1 activation through fat mobilization and gene transcription were conducted in mice. Neuroprotection in vivo was investigated in wild-type and PPAR\u03b1 gene-disrupted mice.\\ud\nKey results: The ECLs OEA, anandamide, noladin ether and virodhamine were found to bind to the purified PPAR\u03b1 ligand binding domain and to increase PPAR\u03b1-driven transcriptional activity. The high affinity synthetic CB1\/2 cannabinoid agonist WIN 55212-2 bound to PPAR\u03b1 equipotently with the PPAR\u03b1 agonist fenofibrate, and stimulated PPAR\u03b1-mediated gene transcription. The phytocannabinoid \u22069 tetrahydrocannabinol was without effect. OEA and WIN 55212-2 induced lipolysis in vivo, while OEA pre-treatment reduced infarct volume from middle cerebral artery occlusion in wild-type, but not in PPAR\u03b1-null mice. OEA treatment also led to increased expression of the NFkB-inhibitory protein, IkB, in mouse cerebral cortex, while expression of the NFkB-regulated protein COX-2 was inhibited.\\ud\nConclusions and implications: These data demonstrate the potential for a range of cannabinoid compounds, of diverse structures, to activate PPAR\u03b1 and suggest that at least some of the neuroprotective properties of these agents could be mediated by nuclear receptor activation","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Nature Publishing Group","rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:lra.le.ac.uk:2381\/8005<\/identifier><datestamp>\n                2010-06-03T15:45:59Z<\/datestamp><setSpec>\n                com_2381_231<\/setSpec><setSpec>\n                com_2381_9550<\/setSpec><setSpec>\n                col_2381_233<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nCannabinoid activation of PPAR\u03b1; a novel neuroprotective mechanism<\/dc:title><dc:creator>\nSun, Y.<\/dc:creator><dc:creator>\nAlexander, S.P.H.<\/dc:creator><dc:creator>\nGarle, M.J.<\/dc:creator><dc:creator>\nGibson, Claire L.<\/dc:creator><dc:creator>\nHewitt, K.<\/dc:creator><dc:creator>\nMurphy, Sean P.<\/dc:creator><dc:creator>\nKendall, D.A.<\/dc:creator><dc:creator>\nBennett, A.J.<\/dc:creator><dc:subject>\ncannabinoids<\/dc:subject><dc:subject>\nN-oleoylethanolamine<\/dc:subject><dc:subject>\nperoxisome proliferator-activated receptors (PPARs)<\/dc:subject><dc:subject>\nneuroprotection<\/dc:subject><dc:description>\nFull text of this item is not currently available on the LRA.  \\ud\nThe final published version is available at http:\/\/www3.interscience.wiley.com\/journal\/121667860\/issue, Doi: 10.1038\/sj.bjp.0707478.<\/dc:description><dc:description>\nBackground and purpose: Although CB1 receptor activation evokes neuroprotection in response to cannabinoids, some cannabinoids have been reported to be peroxisome proliferator activated receptor (PPAR) ligands, offering an alternative protective mechanism. We have, therefore, investigated the ability of a range of cannabinoids to activate PPAR\u03b1 and for N-oleoylethanolamine (OEA), an endogenous cannabinoid-like compound (ECL), to evoke neuroprotection.\\ud\nExperimental approach: Assays of PPAR\u03b1 occupancy and gene transactivation potential were conducted in cell-free and transfected HeLa cell preparations, respectively. In vivo estimates of PPAR\u03b1 activation through fat mobilization and gene transcription were conducted in mice. Neuroprotection in vivo was investigated in wild-type and PPAR\u03b1 gene-disrupted mice.\\ud\nKey results: The ECLs OEA, anandamide, noladin ether and virodhamine were found to bind to the purified PPAR\u03b1 ligand binding domain and to increase PPAR\u03b1-driven transcriptional activity. The high affinity synthetic CB1\/2 cannabinoid agonist WIN 55212-2 bound to PPAR\u03b1 equipotently with the PPAR\u03b1 agonist fenofibrate, and stimulated PPAR\u03b1-mediated gene transcription. The phytocannabinoid \u22069 tetrahydrocannabinol was without effect. OEA and WIN 55212-2 induced lipolysis in vivo, while OEA pre-treatment reduced infarct volume from middle cerebral artery occlusion in wild-type, but not in PPAR\u03b1-null mice. OEA treatment also led to increased expression of the NFkB-inhibitory protein, IkB, in mouse cerebral cortex, while expression of the NFkB-regulated protein COX-2 was inhibited.\\ud\nConclusions and implications: These data demonstrate the potential for a range of cannabinoid compounds, of diverse structures, to activate PPAR\u03b1 and suggest that at least some of the neuroprotective properties of these agents could be mediated by nuclear receptor activation.<\/dc:description><dc:date>\n2010-06-03T15:44:41Z<\/dc:date><dc:date>\n2010-06-03T15:44:41Z<\/dc:date><dc:date>\n2007-10-01<\/dc:date><dc:type>\nArticle<\/dc:type><dc:identifier>\nBritish Journal of Pharmacology, 2007, 152(5), pp. 734\u2013743<\/dc:identifier><dc:identifier>\n0007-1188<\/dc:identifier><dc:identifier>\nhttp:\/\/www3.interscience.wiley.com\/journal\/121667860\/issue<\/dc:identifier><dc:identifier>\nhttp:\/\/dx.doi.org\/10.1038\/sj.bjp.0707478<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/2381\/8005<\/dc:identifier><dc:language>\nen<\/dc:language><dc:format>\nMetadata<\/dc:format><dc:publisher>\nNature Publishing Group<\/dc:publisher>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":[{"title":null,"identifiers":["0007-1188","issn:0007-1188"]}],"language":null,"relations":[],"year":2007,"topics":["cannabinoids","N-oleoylethanolamine","peroxisome proliferator-activated receptors (PPARs)","neuroprotection"],"subject":["Article"],"fullText":null}